• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表皮生长因子受体第20外显子插入突变导致功能改变的结构基础

Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations.

作者信息

Tamirat Mahlet Z, Kurppa Kari J, Elenius Klaus, Johnson Mark S

机构信息

Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, 20520 Turku, Finland.

MediCity Research Laboratories, Institute of Biomedicine, University of Turku, 20520 Turku, Finland.

出版信息

Cancers (Basel). 2021 Mar 5;13(5):1120. doi: 10.3390/cancers13051120.

DOI:10.3390/cancers13051120
PMID:33807850
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7961794/
Abstract

Activating somatic mutations of the epidermal growth factor receptor (EGFR) are frequently implicated in non-small cell lung cancer (NSCLC). While L858R and exon 19 deletion mutations are most prevalent, exon 20 insertions are often observed in NSCLC. Here, we investigated the structural implications of two common EGFR exon 20 insertions in NSCLC, V769insASV and D770insNPG. The active and inactive conformations of wild-type, D770insNPG and V769insASV EGFRs were probed with molecular dynamics simulations to identify local and global alterations that the mutations exert on the EGFR kinase domain, highlighting mechanisms for increased enzymatic activity. In the active conformation, the mutations increase interactions that stabilize the αC helix that is essential for EGFR activity. Moreover, the key Lys745-Glu762 salt bridge was more conserved in the insertion mutations. The mutants also preserved the state of the structurally critical aspartate-phenylalanine-glycine (DFG)-motif and regulatory spine (R-spine), which were altered in wild-type EGFR. The insertions altered the structure near the ATP-binding pocket, e.g., the P-loop, which may be a factor for the clinically observed tyrosine kinase inhibitor (TKI) insensitivity by the insertion mutants. The inactive state simulations also showed that the insertions disrupt the Ala767-Arg776 interaction that is key for maintaining the "αC-out" inactive conformation, which could consequently fuel the transition from the inactive towards the active EGFR state.

摘要

表皮生长因子受体(EGFR)的激活型体细胞突变常与非小细胞肺癌(NSCLC)相关。虽然L858R和外显子19缺失突变最为常见,但外显子20插入在NSCLC中也经常被观察到。在此,我们研究了NSCLC中两种常见的EGFR外显子20插入突变V769insASV和D770insNPG的结构影响。通过分子动力学模拟探究野生型、D770insNPG和V769insASV EGFR的活性和非活性构象,以确定这些突变对EGFR激酶结构域产生的局部和整体变化,突出酶活性增加的机制。在活性构象中,这些突变增加了稳定对EGFR活性至关重要的αC螺旋的相互作用。此外,关键的赖氨酸745 - 谷氨酸762盐桥在插入突变中更为保守。这些突变体还保留了结构关键的天冬氨酸 - 苯丙氨酸 - 甘氨酸(DFG)基序和调节脊柱(R-spine)的状态,而野生型EGFR中的这些结构发生了改变。插入突变改变了ATP结合口袋附近的结构,例如P环,这可能是临床上观察到插入突变体对酪氨酸激酶抑制剂(TKI)不敏感的一个因素。非活性状态模拟还表明,插入突变破坏了维持“αC-out”非活性构象关键的丙氨酸767 - 精氨酸776相互作用,这可能会促使EGFR从非活性状态向活性状态转变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/de441f2687cb/cancers-13-01120-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/b24f25524030/cancers-13-01120-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/92f0cf2087d1/cancers-13-01120-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/998ca8b76553/cancers-13-01120-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/c5c4a2e27e99/cancers-13-01120-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/cb657c6b8fb9/cancers-13-01120-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/90b7913b052e/cancers-13-01120-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/690d6dc6cd54/cancers-13-01120-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/45ca5a6415c1/cancers-13-01120-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/5e774c59fa81/cancers-13-01120-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/8962d6c2baf0/cancers-13-01120-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/de441f2687cb/cancers-13-01120-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/b24f25524030/cancers-13-01120-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/92f0cf2087d1/cancers-13-01120-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/998ca8b76553/cancers-13-01120-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/c5c4a2e27e99/cancers-13-01120-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/cb657c6b8fb9/cancers-13-01120-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/90b7913b052e/cancers-13-01120-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/690d6dc6cd54/cancers-13-01120-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/45ca5a6415c1/cancers-13-01120-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/5e774c59fa81/cancers-13-01120-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/8962d6c2baf0/cancers-13-01120-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c5/7961794/de441f2687cb/cancers-13-01120-g011.jpg

相似文献

1
Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations.表皮生长因子受体第20外显子插入突变导致功能改变的结构基础
Cancers (Basel). 2021 Mar 5;13(5):1120. doi: 10.3390/cancers13051120.
2
Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation.采用分子动力学模拟对 EGFR 外显子 19 缺失突变进行结构特征分析。
PLoS One. 2019 Sep 19;14(9):e0222814. doi: 10.1371/journal.pone.0222814. eCollection 2019.
3
Altered conformational landscape and dimerization dependency underpins the activation of EGFR by C-4 loop insertion mutations.C-4 环插入突变激活 EGFR 的结构基础:构象变化和二聚化依赖性。
Proc Natl Acad Sci U S A. 2018 Aug 28;115(35):E8162-E8171. doi: 10.1073/pnas.1803152115. Epub 2018 Aug 13.
4
Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in -Mutated Non-Small Cell Lung Cancer.新型第三代 EGFR 酪氨酸激酶抑制剂纳喹替尼在 - 突变型非小细胞肺癌中的药效学和结构特征。
Mol Cancer Ther. 2018 Apr;17(4):740-750. doi: 10.1158/1535-7163.MCT-17-1033. Epub 2018 Feb 21.
5
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.肺癌中表皮生长因子受体(EGFR)外显子 20 插入突变的结构、生化和临床特征。
Sci Transl Med. 2013 Dec 18;5(216):216ra177. doi: 10.1126/scitranslmed.3007205.
6
Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations.针对 EGFR 外显子 20 插入突变的 NSCLC 的奥希替尼的临床前建模。
J Thorac Oncol. 2019 Sep;14(9):1556-1566. doi: 10.1016/j.jtho.2019.05.006. Epub 2019 May 17.
7
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.非小细胞肺癌中 EGFR 外显子 20 插入突变:临床前数据及临床意义。
Lancet Oncol. 2012 Jan;13(1):e23-31. doi: 10.1016/S1470-2045(11)70129-2. Epub 2011 Jul 19.
8
NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors.在激酶结构域的调节性C螺旋之后存在表皮生长因子受体(EGFR)外显子20插入的非小细胞肺癌(NSCLC)对已知的EGFR抑制剂反应不佳。
Int J Cancer. 2016 Jul 1;139(1):171-6. doi: 10.1002/ijc.30047. Epub 2016 Mar 25.
9
A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma.一项关于携带罕见表皮生长因子受体(EGFR)突变的非小细胞肺癌的多中心回顾性研究:EGFR外显子19缺失插入的不同亚型表现出非小细胞肺癌的临床特征和预后。
Transl Lung Cancer Res. 2022 Feb;11(2):238-249. doi: 10.21037/tlcr-22-48.
10
Mechanistic insight toward EGFR activation induced by ATP: role of mutations and water in ATP binding patterns.ATP诱导EGFR激活的机制洞察:突变和水在ATP结合模式中的作用
J Biomol Struct Dyn. 2023 Aug-Sep;41(14):6492-6501. doi: 10.1080/07391102.2022.2108497. Epub 2022 Aug 13.

引用本文的文献

1
Targeted Therapy in HER2 Exon 20-Mutant Non-small Cell Lung Cancer With Leptomeningeal Disease: A Case-Based Approach to Treatment Decision-Making.HER2外显子20突变型非小细胞肺癌合并软脑膜疾病的靶向治疗:基于病例的治疗决策方法
Cureus. 2025 Jul 28;17(7):e88905. doi: 10.7759/cureus.88905. eCollection 2025 Jul.
2
STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models.STX-721,一种共价表皮生长因子受体/人表皮生长因子受体2第20外显子抑制剂,利用第20外显子突变的动态蛋白状态,并在多种人类癌症模型中实现独特的突变体选择性。
Clin Cancer Res. 2025 Jul 15;31(14):3002-3018. doi: 10.1158/1078-0432.CCR-24-3833.
3

本文引用的文献

1
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation.利用分子动力学模拟解析激活型表皮生长因子受体体细胞突变的结构效应
J Vis Exp. 2020 May 20(159). doi: 10.3791/61125.
2
Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation.采用分子动力学模拟对 EGFR 外显子 19 缺失突变进行结构特征分析。
PLoS One. 2019 Sep 19;14(9):e0222814. doi: 10.1371/journal.pone.0222814. eCollection 2019.
3
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
EGFR exon 20 insertions mutation in lung adenocarcinoma and its response by high-dose of Furmonertinib: a real-world study.
肺腺癌中表皮生长因子受体(EGFR)第20外显子插入突变及其对高剂量伏美替尼的反应:一项真实世界研究
BMC Cancer. 2025 May 20;25(1):900. doi: 10.1186/s12885-025-14313-7.
4
S100 and CD34 positive spindle cell tumors of the uterine cervix with EGFR mutation: a hitherto unrecognized neoplasm phenotypically and epigenetically overlapping with "NTRK-rearranged spindle cell neoplasms" of the uterus.伴有表皮生长因子受体(EGFR)突变的子宫颈S100和CD34阳性梭形细胞肿瘤:一种在表型和表观遗传学上与子宫“神经营养酪氨酸激酶受体(NTRK)重排梭形细胞肿瘤”重叠的此前未被认识的肿瘤。
Virchows Arch. 2024 Oct 10. doi: 10.1007/s00428-024-03936-z.
5
Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non-small cell lung cancer.非小细胞肺癌中 EGFR 外显子 20 插入突变的流行病学特征和治疗进展。
Thorac Cancer. 2023 Nov;14(33):3247-3258. doi: 10.1111/1759-7714.15127. Epub 2023 Oct 5.
6
and exon 20 insertion/duplication in advanced non-small cell lung cancer: genomic profiling and clinicopathologic features.晚期非小细胞肺癌中第20外显子插入/重复:基因组分析与临床病理特征
Front Oncol. 2023 May 22;13:1163485. doi: 10.3389/fonc.2023.1163485. eCollection 2023.
7
Computational Prediction of Resistance Induced Alanine-Mutation in ATP Site of Epidermal Growth Factor Receptor.表皮生长因子受体 ATP 结合位点的耐药性诱导丙氨酸突变的计算预测。
Int J Mol Sci. 2022 Dec 13;23(24):15828. doi: 10.3390/ijms232415828.
8
Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with exon 20 insertion mutations.中国非小细胞肺癌伴外显子20插入突变的真实世界临床治疗结果
Front Oncol. 2022 Sep 2;12:949304. doi: 10.3389/fonc.2022.949304. eCollection 2022.
9
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.舒沃替尼,一种选择性 EGFR 抑制剂,用于治疗先前治疗过的携带 EGFR 外显子 20 插入突变的非小细胞肺癌。
Cancer Discov. 2022 Jul 6;12(7):1676-1689. doi: 10.1158/2159-8290.CD-21-1615.
表皮生长因子受体外显子 20 插入突变与非小细胞肺癌对奥希替尼的反应。
BMC Cancer. 2019 Jun 17;19(1):595. doi: 10.1186/s12885-019-5820-0.
4
Targeting exon 20 insertion mutations in non-small cell lung cancer.针对非小细胞肺癌中的外显子 20 插入突变。
Signal Transduct Target Ther. 2019 Mar 8;4:5. doi: 10.1038/s41392-019-0038-9. eCollection 2019.
5
COSMIC: the Catalogue Of Somatic Mutations In Cancer.COSMIC:癌症体细胞突变目录。
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947. doi: 10.1093/nar/gky1015.
6
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.一种表皮生长因子受体和人表皮生长因子受体 2 外显子 20 选择性激酶抑制剂在非小细胞肺癌中的作用机制和临床活性。
Nat Med. 2018 May;24(5):638-646. doi: 10.1038/s41591-018-0007-9. Epub 2018 Apr 23.
7
Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.奥希替尼和那扎替尼对表达临床相关表皮生长因子受体突变的细胞的疗效特征分析。
Oncotarget. 2017 Nov 6;8(62):105479-105491. doi: 10.18632/oncotarget.22297. eCollection 2017 Dec 1.
8
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.EGFR和HER2外显子20插入对共价EGFR和HER2抑制剂的反应异质性
Cancer Res. 2017 May 15;77(10):2712-2721. doi: 10.1158/0008-5472.CAN-16-3404. Epub 2017 Mar 31.
9
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2.致癌性缺失突变在 BRAF、EGFR 和 HER2 中的激活机制。
Cancer Cell. 2016 Apr 11;29(4):477-493. doi: 10.1016/j.ccell.2016.02.010. Epub 2016 Mar 17.
10
PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data.PTRAJ和CPPTRAJ:用于处理和分析分子动力学轨迹数据的软件。
J Chem Theory Comput. 2013 Jul 9;9(7):3084-95. doi: 10.1021/ct400341p. Epub 2013 Jun 25.